Jump to content

BK-5-MAPB

From Wikipedia, the free encyclopedia
BK-5-MAPB
Identifiers
  • 1-(1-benzofuran-5-yl)-2-(methylamino)propan-1-one
PubChem CID
Chemical and physical data
FormulaC12H13NO2
Molar mass203.241 g·mol−1
3D model (JSmol)
  • CC(C(=O)C1=CC2=C(C=C1)OC=C2)NC
  • InChI=1S/C12H13NO2/c1-8(13-2)12(14)10-3-4-11-9(7-10)5-6-15-11/h3-8,13H,1-2H3
  • Key:GKZGRACLZFHCFE-UHFFFAOYSA-N

βk-5-MAPB is an entactogenic drug which is both a substituted cathinone and substituted benzofuran, being structurally related to methylone and 5-MAPB. It acts as a monoamine releaser with selectivity for serotonin and has a similar potency to MDMA.[1][2][3]

References

[edit]
  1. ^ WO 2021/252538, Baggott M, "Advantageous benzofuran compositions for mental disorders or enhancement", published 16 December 2021, assigned to Tactogen Inc. 
  2. ^ WO 2023/107653, Baggott MJ, Lofthus SJ, De Leona XM, Singh A, Hudgins CJ, "Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement", published 21 September 2023, assigned to Tactogen Inc. 
  3. ^ WO 2023/107715, Baggott M, Dalziel S, "Specialized combinations for mental disorders or mental enhancement", published 15 June 2023, assigned to Tactogen Inc.